Phase 3 N=657 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Leukemia
Primary: Overall Survival (Induction Phase) — 15.7; 23.7 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=9 Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age
Infection
Primary: The Maximum Plasma Concentration (Cmax) of Ceftaroline After Administration of Ceftaroline Fosamil at a Dose of 8 mg/kg up to a Maximum Dose of 600 mg Via IV Infusion…
Phase 1 N=42 A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)
Insomnia
Primary: Pharmacokinetic Parameter (Bioequivalence): Maximal Drug Concentration (Cmax) — 40.80; 40.21 ng/mL
Phase 4 N=326 A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline to Week 24 in the Disease Activity Score 28 (DAS28) — -3.3; -1.8 Units on a scale
Phase 3 N=124 Treatment of Obsessive Compulsive Disorder in Children
Obsessive-Compulsive Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) — 0.69; 0.34; 0.30 Proportion of Participants with RESPONSE
Phase 4 N=166 Suboptimal Responders to Adefovir Switching to Entecavir
Hepatitis B, Chronic
Primary: Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level <50 IU/mL at Week 12 by Polymerase Chain Reaction Testing — 5.6; 0.0 Percentage of participants
Phase 4 N=716 Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
Alzheimer's Disease
Primary: Core Study: Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living-Severe Impairment Version (ADCS-ADL-SIV) Score at Week 24…
Phase 4 N=63 Optima: Optimizing Prograf Therapy in Maintenance Allografts II
Kidney Transplantation
Primary: Renal Function in Patients Converted From Cyclosporine to Prograf — 0.05; 0; 0.10 Change in serum creatinine (mg/dL)
Phase 2 N=45 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 45 participants
Phase 1 N=51 Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors
Neoplasms
Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Part 1 — 0; 0; 1; 1 participants
N/A N=200 Trial of Non Invasive Ventilation for Respiratoy Distress Syndrome
Prematurity · Respiratory Distress Syndrome
Primary: Need for Endotracheal Ventilation in the First 72 hs of Life — 34; 25 participants — p=<0.05
Phase 2 N=110 Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer
Esophageal Cancer
Primary: Peri-operative Mortality at 30 Days — 0.029 proportion of participants
Phase 1 N=78 Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations
Pharmacokinetic Study in Healthy Participants
Primary: Maximum Observed Concentration (Cmax) of Dasatinib — 114; 106; 110 ng/mL
Phase 3 N=2,201 Occluded Artery Trial (OAT)
Cardiovascular Diseases · Heart Diseases · Myocardial Infarction
Primary: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF) — 230; 219 participants
Phase 1 N=12 Oral Ketamine for Control of Chronic Pain in Children
Chronic Pain
Primary: Number of Participants Tolerating Dose — 3; 3; 3; 1 participants